DealsNov 4, 2026, 05:16 PM
Evommune Licenses EVO570; Raises $30M in Private Placement
AI Summary
Evommune, Inc. has entered into an exclusive license agreement with Hinova Pharmaceuticals Inc. for the worldwide rights (excluding Greater China) to develop, manufacture, and commercialize Hinova's VAV1 degraders, including EVO570. Evommune will pay an upfront fee of $20 million in cash and $10 million in pre-funded warrants, with potential milestone payments of up to $1.1 billion and tiered royalties. Concurrently, Evommune announced a private placement expected to raise approximately $30 million to fund clinical development and general corporate purposes.
Key Highlights
- Evommune enters exclusive license agreement with Hinova Pharmaceuticals for VAV1 degraders, including EVO570.
- Evommune to pay $20 million upfront cash and $10 million in pre-funded warrants to Hinova.
- Potential milestone payments of up to $1.1 billion and tiered royalties on future net sales.
- Evommune announces a concurrent private placement of $30 million in common stock at $6.04 per share.
- The private placement is expected to close on or about November 6, 2026.
- Proceeds from the private placement will be used to advance clinical development programs, including EVO570, and for general corporate purposes.
Price Impact
More from EVMN